Algernon Pharmaceuticals (XCNQ:AGN) Total Liabilities : C$1.87 Mil (As of Nov. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Total Liabilities?

Algernon Pharmaceuticals's Total Liabilities for the quarter that ended in Nov. 2024 was C$1.87 Mil.

Algernon Pharmaceuticals's quarterly Total Liabilities declined from May. 2024 (C$1.93 Mil) to Aug. 2024 (C$1.78 Mil) but then increased from Aug. 2024 (C$1.78 Mil) to Nov. 2024 (C$1.87 Mil).

Algernon Pharmaceuticals's annual Total Liabilities increased from Aug. 2022 (C$2.52 Mil) to Aug. 2023 (C$2.72 Mil) but then declined from Aug. 2023 (C$2.72 Mil) to Aug. 2024 (C$1.78 Mil).

Algernon Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Algernon Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Total Liabilities Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Total Liabilities

Get a 7-Day Free Trial

0.61

1.02

2.52

2.72

1.78

Algernon Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Total Liabilities	Get a 7-Day Free Trial															2.94	3.52	1.93	1.78	1.87

Algernon Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Algernon Pharmaceuticals's Total Liabilities for the fiscal year that ended in Aug. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.775	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.78

Total Liabilities	=	Total Assets (A: Aug. 2024 )	-	Total Equity (A: Aug. 2024 )
	=	3.944	-	2.169
	=	1.78

Algernon Pharmaceuticals's Total Liabilities for the quarter that ended in Nov. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.867	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.87

Total Liabilities	=	Total Assets (Q: Nov. 2024 )	-	Total Equity (Q: Nov. 2024 )
	=	3.655	-	1.788
	=	1.87

Algernon Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Executives

Christopher Moreau	Director, Senior Officer
Christopher Scott Bryan	Senior Officer
James Kinley	Senior Officer
Harry J.f. Bloomfield	Director
Rajpaul Attariwala	Director
Mark Williams	Director
Howard Gutman	Director
Michael Sadhra	Senior Officer
Kulwant Malhi	10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines